Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 | P30518 | 9/20 | 0.62 |
| ▸ | AVPR1A | P37288 | 7/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | OXTR | P30559 | 2/20 | 0.53 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.51 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15963216 | 0.85 | AVPR1A (0.74) | AVPR2AVPR1ASMN1; SMN2AKR1C3 | |
| SCHEMBL28508464 | 0.79 | NOTUM (0.62) | SMN1; SMN2NOTUM | |
| SCHEMBL4866071 | 0.79 | HSD11B1 (0.55) | AVPR2AVPR1AOXTRHSD11B1 | |
| SCHEMBL30456228 | 0.78 | SMN1; SMN2 (0.69) | AVPR2AVPR1ASMN1; SMN2OXTRNOTUM | |
| SCHEMBL4019697 | 0.77 | SMN1; SMN2 (0.79) | SMN1; SMN2NOTUM | |
| SCHEMBL4871254 | 0.76 | TSHR (0.71) | AVPR2AVPR1ASMN1; SMN2OXTRNOTUM | |
| SCHEMBL11193055 | 0.76 | AKR1C3 (0.73) | SMN1; SMN2AKR1C3CYP2C9CYP2C19 | |
| SCHEMBL5421718 | 0.76 | HSD11B1 (0.78) | SMN1; SMN2NOTUMHSD11B1 | |
| SCHEMBL1858662 | 0.76 | HSD11B1 (0.61) | SMN1; SMN2NOTUMHSD11B1 | |
| SCHEMBL27792690 | 0.75 | AKR1C3 (0.82) | AKR1C3CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7368444-B2 | N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-05-06 | — | — | US | disclosed |
| US-20050101600-A1 | N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1475368-A1 | N-CARBAMOYL NITROGEN-CONTAINING FUSED RING COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-11-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101600-A1 | N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient | CNR1, CNR2, NPSR1 | AVPR2 124/4885AVPR1A 276/4885SMN1; SMN2 2595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.